Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Duke University Medical Center

Sites in Durham, NC

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1500
Shown on this page
12
Current sort
Recently updated
Campus scope
Duke University Medical Center, Durham, NC
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Duke University Medical Center, Durham, NC. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 601–612 of 1,500 matching trials with a site at Duke University Medical Center, Durham, NC.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Conditions
Brain Function, Hemiarch Cardiac Procedure
Interventions
Antegrade Perfusion, Retrograde Perfusion
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting Phase 2 Interventional

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

NCT06822972
Status at this site: Recruiting
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Selinexor 40 mg
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting No phase listed Observational

A Long-term Follow-up Study of Gaucher Disease

NCT03190837
Status at this site: Recruiting
Conditions
Gaucher Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
200 participants
Timeline
2017 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting No phase listed Observational Accepts healthy volunteers

ADRC Clinical Cohort (Alzheimer's Disease)

NCT06703541
Status at this site: Recruiting
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
25 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting No phase listed Observational

Developing a Management Approach for Patients With "Late-Onset" Pompe Disease

NCT03694561
Site status not listed — check the official record
Conditions
Pompe Disease, Pompe Disease (Late-onset), GAA Deficiency
Interventions
Observational
Other
Lead sponsor
Duke University
Other
Eligibility
3 Months to 54 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting Phase 1Phase 2 Interventional

ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

NCT07531745
Status at this site: Recruiting
Conditions
Dravet Syndrome
Interventions
ION337
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Durham, North Carolina + 2 more
Conditions
Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Interventions
CTIM-76
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Beverly Hills, California • Denver, Colorado + 11 more
Recruiting Not applicable Interventional

FlexED: Full Threshold ED Substudy

NCT07732829
Status at this site: Recruiting
Conditions
Eating Disorders, Body Image
Interventions
FlexED
Behavioral
Lead sponsor
Duke University
Other
Eligibility
15 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting Phase 2 Interventional

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

NCT06540963
Status at this site: Recruiting
Conditions
Neuroblastoma
Interventions
Tipifarnib, Naxitamab
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
1 Year to 21 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
12
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 9 more
Active, not recruiting Phase 2 Interventional

Neuroblastoma Maintenance Therapy Trial

NCT02679144
Site status not listed — check the official record
Conditions
Neuroblastoma
Interventions
Difluoromethylornithine (DFMO)
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
1 Year to 30 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2033
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 38 more
Recruiting Phase 2 Interventional

Allopregnanolone (Zuranolone) in Post-stroke Depression

NCT06759558
Status at this site: Recruiting
Conditions
Post Stroke Depression
Interventions
Zuranolone
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting No phase listed Observational

Molecular Assessment and Profiling of Liver Transplant Recipients

NCT04793360
Site status not listed — check the official record
Conditions
Liver Transplantation, Biomarkers
Interventions
LiverCare
Device
Lead sponsor
CareDx
Industry
Eligibility
12 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 22 more

About this Duke University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Duke University Medical Center in Durham, NC as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Duke University at any site, browse by condition, or browse by U.S. city.